Cyclooxygenase-2 inhibitors: promise or peril?
The discovery of two isoforms of the cyclooxygenase enzyme, COX-1 and COX-2, and the development of COX-2-specific inhibitors as anti-inflammatories and analgesics have offered great promise that the therapeutic benefits of NSAIDs could be optimized through inhibition of COX-2, while minimizing thei...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
2002
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1781678/ |
| id |
pubmed-1781678 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-17816782007-01-25 Cyclooxygenase-2 inhibitors: promise or peril? Mengle-Gaw, Laurel J Schwartz, Benjamin D Research Article The discovery of two isoforms of the cyclooxygenase enzyme, COX-1 and COX-2, and the development of COX-2-specific inhibitors as anti-inflammatories and analgesics have offered great promise that the therapeutic benefits of NSAIDs could be optimized through inhibition of COX-2, while minimizing their adverse side effect profile associated with inhibition of COX-1. While COX-2 specific inhibitors have proven to be efficacious in a variety of inflammatory conditions, exposure of large numbers of patients to these drugs in postmarketing studies have uncovered potential safety concerns that raise questions about the benefit/risk ratio of COX-2-specific NSAIDs compared to conventional NSAIDs. This article reviews the efficacy and safety profiles of COX-2-specific inhibitors, comparing them with conventional NSDAIDs. 2002-10 /pmc/articles/PMC1781678/ /pubmed/12467519 http://dx.doi.org/10.1080/09629350290000041 Text en |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Mengle-Gaw, Laurel J Schwartz, Benjamin D |
| spellingShingle |
Mengle-Gaw, Laurel J Schwartz, Benjamin D Cyclooxygenase-2 inhibitors: promise or peril? |
| author_facet |
Mengle-Gaw, Laurel J Schwartz, Benjamin D |
| author_sort |
Mengle-Gaw, Laurel J |
| title |
Cyclooxygenase-2 inhibitors: promise or peril? |
| title_short |
Cyclooxygenase-2 inhibitors: promise or peril? |
| title_full |
Cyclooxygenase-2 inhibitors: promise or peril? |
| title_fullStr |
Cyclooxygenase-2 inhibitors: promise or peril? |
| title_full_unstemmed |
Cyclooxygenase-2 inhibitors: promise or peril? |
| title_sort |
cyclooxygenase-2 inhibitors: promise or peril? |
| description |
The discovery of two isoforms of the cyclooxygenase enzyme, COX-1 and COX-2, and the development of COX-2-specific inhibitors as anti-inflammatories and analgesics have offered great promise that the therapeutic benefits of NSAIDs could be optimized through inhibition of COX-2, while minimizing their adverse side effect profile associated with inhibition of COX-1. While COX-2 specific inhibitors have proven to be efficacious in a variety of inflammatory conditions, exposure of large numbers of patients to these drugs in postmarketing studies have uncovered potential safety concerns that raise questions about the benefit/risk ratio of COX-2-specific NSAIDs compared to conventional NSAIDs. This article reviews the efficacy and safety profiles of COX-2-specific inhibitors, comparing them with conventional NSDAIDs. |
| publishDate |
2002 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1781678/ |
| _version_ |
1611393537125908480 |